Below are some of the key findings from this splenomegaly therapeutics market analysis report
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Get a FREE sample now!
Global Splenomegaly Therapeutics Industry Overview
The increasing demand for targeted therapy is one of the critical reasons that will drive splenomegaly therapeutics market growth. Targeted therapy is a novel approach used to treat malignancies without harming the peripheral healthy cells of the body. This is done by singling out and targeting the specific receptors present in cancer cells. The therapeutic benefits of this innovative approach are encouraging many institutes to increase their R&D investments in targeted therapy. The adoption of molecular-targeted therapies for the treatment of splenomegaly to reduce the spleen size will continue to improve.
Along with the adoption of targeted therapy, the expanding research on the molecular pathogenesis of splenomegaly has enabled researchers to understand the mechanism of action and disease-specific factors that cause splenomegaly. This has enabled them to understand driver mutations and develop many JAK-2 protein inhibitors to minimize the spleen volume in many patients with myelofibrosis. Consequently, this will boost the adoption of splenomegaly therapeutics and drive splenomegaly therapeutics market growth at a CAGR of over 3% during the forecast period.
Top splenomegaly therapeutics companies covered in this market research report
The global splenomegaly therapeutics market is fairly fragmented. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by companies, this splenomegaly therapeutics industry analysis report will help clients identify new growth opportunities and design innovative strategies to improve their market share.
The report offers a complete analysis of various companies including:
- GlaxoSmithKline plc
- Incyte Corporation
- Merck & Co., Inc.
- Novartis AG
- Sanofi
Splenomegaly therapeutics market segmentation based on geographic regions
- Asia
- Europe
- North America
- ROW
North America will account for the largest splenomegaly therapeutics market share throughout the forecast period. The increasing focus of governments and non-government organizations in creating awareness regarding the early diagnosis and management of splenomegaly is one of the primary reasons for the high growth of the splenomegaly therapeutics market in this region.
Splenomegaly therapeutics market segmentation based on product
The drug therapy segment will account for the highest splenomegaly therapeutics market share because of the growing consumption of antibiotic drugs to treat splenomegaly caused by bacterial or viral infection. Additionally, patients suffering from congestive, infiltrative, neoplastic, and immune splenomegaly increasingly rely on drugs more than vaccination.
Key highlights of the global splenomegaly therapeutics market for the forecast years 2019-2023
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the splenomegaly therapeutics market during the next five years
- Precise estimation of the global splenomegaly therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the splenomegaly therapeutics industry across various geographies such as Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details on factors that will challenge the growth of splenomegaly therapeutics companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- 2.1 Preface
- 2.2 Preface
- 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Drug therapy - Market size and forecast 2018-2023
- Vaccination - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
- Congestive splenomegaly
- Infiltrative splenomegaly
- Neoplastic splenomegaly
- Immune splenomegaly
PART 10: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- GlaxoSmithKline plc
- Incyte Corporation
- Merck & Co., Inc.
- Novartis AG
- Sanofi
PART 16: APPENDIX
- Research methodology
- List of abbreviations
PART 17: EXPLORE TECHNAVIO